Abstract
Due to their role in the inhibition of non nucleoside reverse transcriptase, 4,5,6,7-Tetrahydro- 5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-ones (TIBO) derivatives present a significant importance as a potent chemotherapeutic agent against the AIDS disease. In this work, we report our attempt to find out the other factors required in quantitative structure-activity relationship for a set of 89 TIBO derivatives.
In vitro Anti HIV activity of TIBO derivatives logIC50 expressed as log1/C values were considered as a biological activity parameter. The QSAR study of the dataset of 89 TIBO derivatives was performed using different parameters namely Topological, physicochemical, hydrophobic descriptors and indicator parameters. Multiple regression analysis performed to obtain QSAR model and to capture the descriptor other than the logP.
The QSAR study highlights the logP, Is and surface area grid (SAG) descriptors, that affect the anti HIV activity of these TIBO derivatives. SAG is found as the cofactor working with hydrophobicity of TIBO derivatives. Eventually, the study provides a strong foundation to design new and more potent inhibitors of HIV-1 RT.
References
R.M Gulick, New antiretroviral Drugs. Clin. Microbiol. Infect. 9,(2003),186-193.
M.Goette, M.A Wainberg, In Viral Infections and Treatment; Rubsamen-Waigmann, Ed.; Marcel Decker: New York, 30, (2003), 505-521.
E. De Clercq, Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Past, present, and future. Chem. Biodivers.,1, (2004), 44-64.
J. Balzarini , Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr. Top. Med. Chem., 4, (2004), 921-944.
C.M Tarby Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors. Curr. Top. Med. Chem., 4, 2004, 1045-1057.
Boone L.R Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.Curr. Opin. Investig. Drugs , 7,(2006), 128-135.
A. Basavapathruni, K.S Anderson, Developing novel nonnucleoside HIV-1 reverse transcriptase inhibitors: beyond the butterfly, Curr. Pharmaceut. Res., 12, (2006), 1857- 1865.
J.M.A Lange, Efficacy and durability of nevirapine in antiretroviral drug naïve patients. JAIDS, 34, (2003), S40- 52.
L.A Sorbera, J Castaner., M Bayes. Capravirine - Anti-HIV agent - Reverse transcriptase inhibitor, Drugs Future, 28, (2003), 1149-1158.
Fortin C., Joly V., Efavirenz for HIV-1 infection in adults: an overview Expert Rev. Anti-infect. Ther. 2, (2004), 671- 684.
S.L Davies, J Castaner. J.S Silvestre, M Bayes., Etravirine - Anti-HIV agent reverse transcriptase inhibitor. Drugs Future, 30, (2005), 462-468.
R Silvestri, M Artico, Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies. J Med Chem 46,(2003), 2482-2493.
O.J.D’Cruz, F.M Uckun, Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Enzym. Inhib. Med. Chem., 21, (2006), 329- 350.
M.A Wainberg, HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors JAIDS, 34, (2003), S2-7.
J. Martinez, P Coplan, M.A Wainberg, Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies? Antivir. Res., 71,(2006), 343-350.
Sluis-Cremer N., Temiz N.A, Bahar I., Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr. HIV Res., 2,(2004), 323-332.
K Das, P.J Lewi, S.H Hughes, E Arnold, Crystallography and the Design of Anti-AIDS Drugs: Conformational Flexibility and Positional Adaptability are Important in the Design of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors, Prog. Biophys. Mol. Biol., 88, (2005), 209-231.
Z Zhang, R Hamatake, Z Hong, Clinical utility of current NNRTIs and perspectives of new agents in this class under development. Antivir. Chem. Chemother., 15, (2004), 121- 134.
Quirk E., McLeod H., Powderly W., The pharmacogenetics of antiretroviral therapy: a review of studies to date. Clin. Infect. Dis., 39, (2004), 98-106.
Kappelhoff B.S , van Leth F. , MacGregor T.R, Lange J, Beijnen J.H, Huitema A.D, 2NN Study Group. Antivir Ther 10 (1) (2005), 145-55.
D’Cruz O.J, Uckun F.M, Dawn of non-nucleoside inhibitor- based anti-HIV microbicides J. Antimicrob. Chemother., 57, (2006), 411-423.
N Kontorinis, D Dietrich, Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin. Liver Dis., 23, (2003), 173-182.
D.T Dietrich, P.A Robinson. J Love , J.O Stern, Drug- induced liver injury associated with the use of non-nucleoside reverse-transcriptase inhibitors Clin. Infect. Dis., 38, (2004), S80-89.
N Abrescia, M D’Abbraccio, M Figoni, A Busto, A Maddaloni, M DeMarco., Hepatotoxicity of antiretroviral drugs. Curr. Pharm. Des. 11, (2005), 3697-3710.
D Nolan., Do Non-Nucleoside Reverse Transcriptase Inhibitors Contribute to Lipodystrophy? Drug Safety, 28, (2005), 1069-1074.
K.A Cohen, J Hopkins, R.H.Ingraham., Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. J Biol Chem. 266, (1991), 14670-14674.
L.Bacheler, S Jeffrey, G Hanna, Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol. 75, (2001), 4999-5008.
D.D Richman, D Havlir, J Corbeil, Evirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 68, (1994), 1660-1666.
J.S Montaner, P Reiss , D Cooper, A randomized, double- blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 279, (1998), 930-937.
S Staszewski, J Morales-Ramirez, K.T Tashima, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 341,(1999), 1865-1873.
R.L Murphy, C Katlama, V Johnson. The Atlantic Study. A randomized open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48-week data. Abstract LB-
Paper presented at: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco.
G.K Robbins, V De Gruttola, RW Shafer, Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 349, (2003), 2293-2303.
M.A Albrecht, R.J Bosch, S.M Hammer. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 345, (2002), 398-407.
Rajni Garg,. Satya P Gupta, Hua Gao, Suresh Babu Mekapati, Asim Kumar Debnath, and Corwin Hansch, Comparative Quantitative Structure-Activity Relationship Studies on Anti-HIV Drugs., Chem. Rev . 99, (1999), 3525- 3601.
A.T Balaban, Highly discriminating Topological Index., Chem. and Phy. Lett.,89, (1982), 399-404.
H Wiener, Structural determination of Paraffin Boiling points., J.Am. Chem. Soc. 69, (1947), 17-20.
L.B Kier and L.H Hall Molecular connectivity in structure activity analysis., Research studies press., Wiley Chichester U.K., (1986).
Schultz T.W and Crownin M.T.D ,Quantitative Structure Activity relationship of Weak acid respiratory uncoupler to vibrio fisheri., Environ. Tox. & chem.. 16, (1997), 357-360. 39 C Croux., K Joossens, Influence of observations on the misclassification probability in quadratic discriminant analysis. J Multivar Anal. 96, (2005), 348–403.
J Devillers Neuronal network in QSAR and drug design. Academic Press, London; 1996.
Z Zhou, M Madrid., J.D Madura, Docking of non- nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase. Proteins. 49 (2002), 529-542.
Y.Z. Chen, X.L.Gu, Z.W.Cao, Can an optimization/scoring procedure in ligand–protein docking be employed to probe drug-resistant mutations in proteins? J. Mol. Graphics Modell,. 19, (2001), 560-570.
M.A.L.Eriksson, J Pitera, P.A.Kollman,Prediction of t he binding free energies of new TIBO like HIV-1 reverse transcriptase using a combination of PROFEC, PB/SA, CMC/MD, and free energies calculations. J. Med. Chem. 42, (1999), 868-881.
How to cite your article:
Thakur M., Thakur A., Ojha L., “Surface area grid in modeling of anti-HIV activity of tibo derivatives ”, Int. J. Res. Dev. Pharm. L. Sci., 2014, 3(3), pp. 983-992.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array